IRC
ADAP

Investors Research Corp’s Adaptimmune Therapeutics ADAP Stock Holding History

Investors Research Corp’s Portfolio ADAP Stock Details ADAP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100
Closed -$13 – 845
2025
Q3 		$13 Hold
100
– – ﹤0.01% 867
2025
Q2 		$24 Hold
100
– – ﹤0.01% 921
2025
Q1 		$20 Hold
100
– – ﹤0.01% 958
2024
Q4 		$54 Hold
100
– – ﹤0.01% 932
2024
Q3 		$95 Hold
100
– – ﹤0.01% 959
2024
Q2 		$97 Hold
100
– – ﹤0.01% 1038
2024
Q1 		$158 Hold
100
– – ﹤0.01% 1004
2023
Q4 		$79 Hold
100
– – ﹤0.01% 1046
2023
Q3 		$78 Sell
100
-100
-50% -$84 ﹤0.01% 1056
2023
Q2 		$185 Buy
+200
New +$238 ﹤0.01% 1054

Other funds holding ADAP

JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
EF
Empirical Finance Havertown, Pennsylvania $2.13B AUM 29.56% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Investors Research Corp's ADAP Position: Q4 2025 in Review

Investors Research Corp sold out of Adaptimmune Therapeutics (ADAP) in Q4 2025, closing a stake of 100 shares — an estimated $13 sold.

Investors Research Corp first reported a position in ADAP in Q2 2023 and held it in 10 quarters. The position peaked at $185 in Q2 2023. 10 funds tracked by Wall St. Rank hold ADAP as of Q4 2025.

  • Investors Research Corp reported no remaining Adaptimmune Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Investors Research Corp sold 100 Adaptimmune Therapeutics shares in Q4 2025, an estimated $13.
  • Investors Research Corp first reported a position in Adaptimmune Therapeutics in Q2 2023 and held it in 10 quarters.
  • Investors Research Corp's Adaptimmune Therapeutics position peaked at $185 in Q2 2023.
  • 10 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2025.

Based on Investors Research Corp's 13F filing for Q4 2025, filed 6 Jan 2026.